Incyte Corporation (INCY)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Gross profit | US$ in thousands | 3,438,110 | 3,187,640 | 2,835,280 | 2,535,370 | 2,044,510 |
Revenue | US$ in thousands | 3,693,100 | 3,394,640 | 2,986,270 | 2,666,700 | 2,158,760 |
Gross profit margin | 93.10% | 93.90% | 94.94% | 95.08% | 94.71% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $3,438,110K ÷ $3,693,100K
= 93.10%
The gross profit margin of Incyte Corp. has shown a decreasing trend over the past five years, declining from 94.71% in 2019 to 93.10% in 2023. Despite the slight fluctuation in the intervening years, the overall trend suggests a gradual erosion of gross profit margin. This may indicate increasing costs of goods sold relative to revenue generated, potentially squeezing the company's profitability. It is important for Incyte Corp. to closely monitor and address the factors contributing to this trend to maintain strong financial health and sustainable profitability in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Incyte Corporation
INCY
93.10%
Arrowhead Pharmaceuticals Inc
ARWR
52.77%
Charles River Laboratories
CRL
76.43%
Exelixis Inc
EXEL
66.38%
IQVIA Holdings Inc
IQV
10.15%
Medpace Holdings Inc
MEDP
19.06%